Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg).
Ekaterina KraussSilke TelloJochen WilhelmJohanna SchmidtMark StoehrWerner SeegerRuth C DartschBruno CrestaniAndreas GuentherPublished in: Journal of clinical medicine (2020)
We report the effectiveness of pirfenidone in a European "real world" IPF cohort with outcome data extending up to 9 years. Global analyses demonstrated a positive effect of pirfenidone on the decline of the lung function over time. Survival was dependent on Gender-Age-Physiology (GAP) score and age prior to therapy.
Keyphrases
- idiopathic pulmonary fibrosis
- lung function
- interstitial lung disease
- randomized controlled trial
- electronic health record
- systematic review
- cystic fibrosis
- chronic obstructive pulmonary disease
- air pollution
- big data
- mental health
- data analysis
- stem cells
- free survival
- rheumatoid arthritis
- machine learning
- deep learning